(Q30305594)

16 June 2017

1 reference

title

The evaluation and management of platelet refractoriness and alloimmunization (English)

1 reference

16 June 2017

Delaflor-Weiss E

1

1 reference

PubMed ID

10782501

16 June 2017

Mintz PD

series ordinal

2

1 reference

16 June 2017

1 April 2000

1 reference

Transfusion Medicine Reviews

16 June 2017

1 reference

16 June 2017

14

1 reference

16 June 2017

2

1 reference

16 June 2017

180-196

1 reference

THE RELATION OF BLOOD PLATELETS TO HEMORRHAGIC DISEASE

16 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Effect of platelet transfusion on hemorrhage in patients with acute leukemia: An autopsy study

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

The Prophylactic Treatment of Thrombocytopenic Leukemic Patients with Platelets: a Double Blind Study

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

PLATELET SEQUESTRATION IN MAN. I. METHODS.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

The value of 10-minute posttransfusion platelet counts

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

The definition of refractoriness to platelet transfusions

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Factors influencing 20-hour increments after platelet transfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Determination of the rate of reduction in platelet counts in recipients of hematopoietic stem and progenitor cell transplant: clinical implications for platelet transfusion therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

White cell reduction in platelet concentrates and packed red cells by filtration: a multicenter clinical trial. The Trap Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

The influence of irradiation on stored platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

A randomized trial comparing the use of fresh and stored platelets in the treatment of bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Comparison of posttransfusion recoveries achieved with either fresh or stored platelet concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Influence of clinical status on the efficiency of stored platelet transfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Detection of platelet activation with monoclonal antibodies and flow cytometry. Changes during platelet storage

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Progressive platelet activation with storage: evidence for shortened survival of activated platelets after transfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Effect of storage temperature on maintenance of platelet viability--deleterious effect of refrigerated storage

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Factors influencing the transfusion response to HLA-selected apheresis donor platelets in patients refractory to random platelet concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation--a prospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Relative importance of immune and non-immune causes of platelet refractoriness

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Clinical and laboratory factors associated with platelet transfusion refractoriness: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

ABO compatibility can influence the results of platelet transfusion. Results of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Circulating immune complexes involving the ABO system after platelet transfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

ABH antibodies causing platelet transfusion refractoriness

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Transfusion of ABO-mismatched platelets leads to early platelet refractoriness

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Minimal expression of blood group A antigen on thrombocytes from A2 individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Selection of unrelated compatible platelet donors by lymphocyte HL-A matching

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components--a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Immunological Unresponsiveness Induced by Ultraviolet Radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Disappearance of HLA and platelet-specific antibodies in acute leukaemia patients alloimmunized by multiple transfusions

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Development of lymphocytotoxic and platelet reactive antibodies: a prospective study in patients with acute leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

The kinetics of unmatched and HLA-matched 111in-labelled homologous platelets in recipients with chronic marrow hypoplasia and anti-platelet immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

The predictive value of crossmatching platelet transfusion for alloimmunized patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Successful transfusion of platelets “mismatched” for HLA antigens to alloimmunized thrombocytopenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Platelet transfusion from donors mismatched for crossreactive HLA antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Expression of HLA-B12 on Platelets, on Lymphocytes and in Serum: a Quantitative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

HLA antigens of platelets. IV. Influence of "private" HLA--B locus specificities on the expression of Bw4 and Bw6 on human platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Selection of platelets for refractory patients by HLA matching and prospective crossmatching

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Crossmatch-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Independent roles for platelet crossmatching and HLA in the selection of platelets for alloimmunized patients

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

A flow cytometric platelet immunofluorescence crossmatch for predicting successful HLA matched platelet transfusions

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Selection of compatible platelet donors: a prospective evaluation of three cross-matching techniques

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Use of a Solid Phase Red Blood Cell Adherence Method for Pretransfusion Platelet Compatibility Testing

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Relationship of HLA and platelet-reactive antibodies in alloimmunized patients refractory to platelet therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Frequency and specificity of platelet-specific alloantibodies in HLA-immunized haematologic-oncologic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Serological screening, using three different test systems of platelet-transfused patients with hematologic-oncologic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Simple method for differentiating between HLA and platelet-specific antibodies by flow cytometry

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Immunological aspects of platelet transfusions.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Alloimmunization to platelet-specific antigens on glycoproteins IIb-IIIa and Ib/IX in multiply transfused thrombocytopenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Specificities of anti-platelet antibodies in multitransfused patients with haemato-oncological disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Platelet alloimmunization after multiple transfusions: a prospective study of 50 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Antibodies to platelet glycoprotein V in polytransfused patients with haematological disease

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Successful treatment of platelet transfusion refractoriness: the use of platelet transfusions matched for both human leucocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunized patients with leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Rapid determination of platelet alloantigen genotypes by polymerase chain reaction using allele-specific primers

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Platelet autoantibodies in septicaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

CMV infection after allogeneic bone marrow transplantation is associated with the occurrence of various autoantibodies and monoclonal gammopathies.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Acquired autoimmune thrombocytopenia after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Laboratory investigation of drug-induced immune thrombocytopenias.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Evidence that circulating immune complexes remove transfused platelets from the circulation

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Antibodies to plasma proteins: an association with platelet transfusion refractoriness

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Autologous platelet transfusion in alloimmunized patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Control of bleeding in patients with immune and nonimmune thrombocytopenia with aminocaproic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Improved response of patients refractory to random-donor platelet transfusions by intravenous gamma globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

High dose intravenous gammaglobulin and platelet transfusions in leukaemic HLA-immunized patients

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

High-dose intravenous gamma globulin to suppress alloimmune destruction of donor platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Intravenous gamma globulin decreases platelet-associated IgG and improves transfusion responses in platelet refractory states

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Improvement of post platelet transfusion increments following intravenous immunoglobulin therapy for leukaemic HLA-immunized patients

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Treatment of platelet alloimmunization with intravenous immunoglobulin. Two case reports and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Intravenous immune globulin for patients alloimmunized to random donor platelet transfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Effect of Normal Human Serum on the Binding of Specific Antibodies and Platelet-unrelated Immune Complexes to Human Platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Plasma exchange for platelet alloimmunization.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

The use of anti-D to improve post-transfusion platelet response: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Treatment of refractoriness to platelet transfusion by protein A column therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

The application of protein A immunoadsorption to remove platelet alloantibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Treatment of refractoriness to platelet transfusion by protein A column therapy: the role of the IgG subclasses

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Temporary suppression of circulating antiplatelet alloantibodies by the massive infusion of fresh, stored, or lyophilized platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Treatment of platelet-alloimmunization with cyclosporin A in a patient with aplastic anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Cyclosporin for treatment of life-threatening alloimmunization

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Approaches to preventing or reversing platelet alloimmunization using animal models

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Anti-thymocyte globulin (ATG) can eliminate platelet refractoriness

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

An alloimmunized, thrombocytopenic patient successfully transfused with acid-treated, random-donor platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

HLA class I-eluted platelets as an alternative to HLA-matched platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Acid elution of platelets HLA-class I antigens in the treatment of a refractory patient

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Vinblastine-loaded platelet transfusion in an alloimmunized patient

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

The treatment of idiopathic thrombocytopenia with vinblastine-loaded platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

Platelet growth factors: potential impact on transfusion medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

1 reference

7 January 2021

Human platelet-specific alloantigens: update

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2800%2980007-3

7 January 2021

10.1016/S0887-7963(00)80007-3

Identifiers

DOI

1 reference

16 June 2017

1 reference

PubMed ID

10782501